Patents by Inventor Sarah Devos

Sarah Devos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating Alzheimer's disease
    Patent number: 11781135
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: October 10, 2023
    Assignees: Washington University, Biogen MA Inc.
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo
  • TAU MODULATORS AND METHODS AND COMPOSITIONS FOR DELIVERY THEREOF
    Publication number: 20230270774
    Abstract: The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: August 31, 2023
    Applicants: Sangamo Therapeutics, Inc., The General Hospital Corporation
    Inventors: Annemarie Ledeboer, Bryan Zeitler, H. Steve Zhang, Sarah DeVos, Bradley T. Hyman, Susanne Wegmann
  • Tau modulators and methods and compositions for delivery thereof
    Patent number: 11504389
    Abstract: The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: November 22, 2022
    Assignees: Sangamo Therapeutics, Inc., The General Hospital Corporation
    Inventors: Annemarie Ledeboer, Bryan Zeitler, H. Steve Zhang, Sarah DeVos, Bradley T. Hyman, Susanne Wegmann
  • METHODS FOR MODULATING TAU EXPRESSION FOR REDUCING SEIZURE AND MODIFYING A NEURODEGENERATIVE SYNDROME
    Publication number: 20200032257
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Application
    Filed: March 11, 2019
    Publication date: January 30, 2020
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo
  • Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
    Patent number: 10273474
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 30, 2019
    Assignees: WASHINGTON UNIVERSITY, ISIS PHARMACEUTICALS, INC.
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo
  • TAU MODULATORS AND METHODS AND COMPOSITIONS FOR DELIVERY THEREOF
    Publication number: 20180153921
    Abstract: The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Annmarie Ledeboer, Bryan Zeitler, H. Steve Zhang, Sarah DeVos, Bradley T. Hyman, Susanne Wegmann
  • METHODS FOR MODULATING TAU EXPRESSION FOR REDUCING SEIZURE AND MODIFYING A NEURODEGENERATIVE SYNDROME
    Publication number: 20150275205
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 1, 2015
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo